

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

44342.013100

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

09/913521

INTERNATIONAL APPLICATION NO.

PCT/IP00/00778

INTERNATIONAL FILING DATE

February 14, 2000

PRIORITY DATE CLAIMED

February 15, 1999

TITLE OF INVENTION

CHAIN-SHORTENED POLYNUCLEOTIDE AND METHOD FOR PREPARATION THEREOF

APPLICANT(S) FOR DO/EO/US

Shinji MATSUYAMA, Kouichi ISHIYAMA, Junzo SEKI, and Tadaaki OHGI

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.
4. ☒ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
 - a. ☒ is attached hereto (required only if not communicated by the International Bureau).
 - b. ☒ has been communicated by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a. ☒ is attached hereto.
 - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☒ have been communicated by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
8. ☒ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
10. ☒ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☒ A copy of the International Search Report (PCT/ISA/210).

Items 13 to 20 below concern document(s) or information included:

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☒ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
20. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
21. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
22. ☒ Certificate of Mailing by Express Mail
23. ☐ Other items or information:

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR <div style="font-size: 1.5em; font-weight: bold;">09/913521</div>	INTERNATIONAL APPLICATION NO. <div style="font-weight: bold;">PCT/JP00/00778</div>	ATTORNEY'S DOCKET NUMBER <div style="font-weight: bold;">44342.013100</div>
24. The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) : <input checked="" type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1000.00 <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$860.00 <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$710.00 <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$690.00 <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00		CALCULATIONS PTO USE ONLY <div style="border: 1px solid black; padding: 5px;"> <div style="text-align: right; font-weight: bold;">\$1,000.00</div> </div>
ENTER APPROPRIATE BASIC FEE AMOUNT =		\$1,000.00
Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492 (e)). <input type="checkbox"/> 20 <input type="checkbox"/> 30		\$0.00
CLAIMS	NUMBER FILED	NUMBER EXTRA
Total claims	19 - 20 =	0
Independent claims	4 - 3 =	1
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>		\$0.00
TOTAL OF ABOVE CALCULATIONS =		\$1,080.00
<input type="checkbox"/> Applicant claims small entity status. (See 37 CFR 1.27). The fees indicated above are reduced by 1/2.		\$0.00
SUBTOTAL =		\$1,080.00
Processing fee of \$130.00 for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492 (f)). <input type="checkbox"/> 20 <input type="checkbox"/> 30		\$0.00
TOTAL NATIONAL FEE =		\$1,080.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). <input type="checkbox"/>		\$0.00
TOTAL FEES ENCLOSED =		\$1,080.00
		Amount to be: refunded \$ charged \$
a. <input type="checkbox"/> A check in the amount of _____ to cover the above fees is enclosed. b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. 501561 in the amount of \$1,080.00 to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. _____. A duplicate copy of this sheet is enclosed. d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.		
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.		
SEND ALL CORRESPONDENCE TO:		
Greenberg Traurig LLP 885 Third Avenue - 21st floor New York, NY 10022		<div style="text-align: right;"> SIGNATURE </div> <div style="text-align: right;"> Alan P. Force NAME </div> <div style="text-align: right;"> 39,673 REGISTRATION NUMBER </div> <div style="text-align: right;"> August 13, 2001 DATE </div>

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Matsuyama, et al.

Group Art Unit: to be assigned

Application No.: to be assigned

Examiner: to be assigned

Filed: herewith

Attorney Docket No.: 44342.013100

For: CHAIN-SHORTENED
POLYNUCLEOTIDE AND METHOD FOR
PREPARATION THEREOF

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicant respectfully requests entry of the following amendments and comments into the file of the above identified application prior to the examination thereof.

In the Claims:

Amend as follows:


1. (amended) A chain-shortened polynucleotide or salt thereof, comprising phosphodiester bonds, wherein up to about 3 percent of the phosphodiester bonds are 2'-5' phosphodiester bonds.

2. (amended) The chain-shortened polynucleotide or salt thereof according to claim 1, wherein the polynucleotide is polyinosinic acid or analogue thereof, polycytidylic acid or analogue thereof, polyadenylic acid or analogue thereof, or polyuridylic acid or analogue thereof.

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

Signature



Date

8/13/01

3. (amended) The chain-shortened polynucleotide or salt thereof according to claim 1, wherein the polynucleotide or salt thereof has an average chain length of between about 0.1 k bases and about 1 k bases.

4. (amended) The chain-shortened polynucleotide or salt thereof according to claim 1, wherein the polynucleotide or salt thereof is in the form of a double stranded chain-shortened polynucleotide or salt thereof formed from two chain-shortened polynucleotides or salts thereof which are capable of forming a double strand.

5. (amended) The double stranded chain-shortened polynucleotide or salt thereof according to claim 4, wherein the two chain-shortened polynucleotides capable of forming a double strand are selected from the group consisting of polyinosinic acid and polycytidylic acid, polyadenylic acid and polyuridylic acid, polyinosinic acid analogue and polycytidylic acid, polyinosinic acid and polycytidylic acid analogue, polyinosinic acid analogue and polycytidylic acid analogue, polyadenylic acid analogue and polyuridylic acid, polyadenylic acid and polyuridylic acid analogue, and polyadenylic acid analogue and polyuridylic acid analogue.

6. (amended) A method for preparing the chain-shortened polynucleotide or salt thereof, the method comprising reacting a polynucleotide or salt thereof in a solution at about pH 7 to about pH 10 and at temperature between about 20 and about 110°C to shorten the chain, thereby forming a chain-shortened polynucleotide or salt thereof, comprising phosphodiester bonds, wherein up to about 3 percent of the phosphodiester bonds are 2'-5' phosphodiester bonds.

7. (amended) A method for preparing the chain-shortened polynucleotide or salt thereof, the method comprising treating a polynucleotide or salt thereof with a phosphodiesterase for chain-shortening, thereby forming a chain-shortened polynucleotide or salt thereof, comprising phosphodiester bonds, wherein up to about 3 percent of the phosphodiester bonds are 2'-5' phosphodiester bonds.

8. (amended) A composition comprising a complex formed from a carrier effective for introducing a medicament into a cell and a chain-shortened polynucleotide or salt thereof as an essential ingredient, wherein the chain-shortened polynucleotide or salt thereof comprises phosphodiester bonds, such that up to about 3 percent of the phosphodiester bonds are 2'-5' phosphodiester bonds.

12. (amended) The composition according to Claim 8, wherein the composition is in the form of a pharmaceutical preparation.

13. The composition according to Claim 12, wherein the pharmaceutical preparation comprises an interferon inducing agent, immune activating agent, intracellular nuclease activating agent, cancer treating agent or preventive agent, or hepatitis treating agent or preventive agent.

Add the following new claims:

14. (new) The method according to 6, wherein the polynucleotide is polyinosinic acid or analogue thereof, polycytidylic acid or analogue thereof, polyadenylic acid or analogue thereof, or polyuridylic acid or analogue thereof.

15. (new) The method according to claim 7, wherein the polynucleotide is polyinosinic acid or analogue thereof, polycytidylic acid or analogue thereof, polyadenylic acid or analogue thereof, or polyuridylic acid or analogue thereof.

16. (new) The composition according to claim 8, wherein the polynucleotide is polyinosinic acid or analogue thereof, polycytidylic acid or analogue thereof, polyadenylic acid or analogue thereof, or polyuridylic acid or analogue thereof.

17. (new) The composition according to claim 8, wherein the polynucleotide or salt thereof has an average chain length of between about 0.1 k bases and about 1 k bases.

18. (new) The chain-shortened polynucleotide or salt thereof according to claim 8, wherein the polynucleotide or salt thereof is in the form of a double stranded

chain-shortened polynucleotide or salt thereof formed from two chain-shortened polynucleotides or salts thereof which are capable of forming a double strand.

19. (new) The double stranded chain-shortened polynucleotide or salt thereof according to Claim 18, wherein the two chain-shortened polynucleotides capable of forming a double strand are selected from the group consisting of polyinosinic acid and polycytidylic acid, polyadenylic acid and polyuridylic acid, polyinosinic acid analogue and polycytidylic acid, polyinosinic acid and polycytidylic acid analogue, polyinosinic acid analogue and polycytidylic acid analogue, polyadenylic acid analogue and polyuridylic acid, polyadenylic acid and polyuridylic acid analogue, and polyadenylic acid analogue and polyuridylic acid analogue.

REMARKS


Claims 1 to 13, as amended, and new claims 14 to 19 appear in this application for the Examiner's review and consideration. The new claims are directed to preferred embodiments of the invention. The new claims and amendments are fully supported by the specification and the claims as originally filed. Therefore, there is no issue of new matter. Substitute claim pages are attached for the convenience of the Examiner.

Applicants submit that the entire application is in condition for allowance, early notice of which would be appreciated.

No fees are believed to be due for the filing of this Preliminary Amendment. Should any fees be required, however, please charge such fees to Deposit Account No. 501561.

Respectfully submitted,

Date August 13, 2001

 39,673
Alan P. Force (Reg. No.)

Greenberg Traurig
885 Third Avenue
New York, NY 10022-4898

212-801-2100

Amended claims for U.S. National Stage Patent Application corresponding to
PCT/JP00/00778

1. (amended) A chain-shortened polynucleotide or salt thereof,
[characterized in that the] comprising phosphodiester bonds, wherein up to about 3
percent of the phosphodiester bonds are [proportion of a] 2'-5' phosphodiester bonds [is
up to 3% based on the whole phosphodiester bonds].

2. (amended) The chain-shortened polynucleotide or salt thereof
according to [Claim] claim 1, wherein the polynucleotide is polynosinic acid or analogue
thereof, polycytidylic acid or analogue thereof, polyadenylic acid or analogue thereof, or
polyuridylic acid or analogue thereof.

3. (amended) The chain-shortened polynucleotide or salt thereof
according to [Claim] claim 1 [or 2], wherein the polynucleotide or salt thereof has an
average chain length [is] of between about 0.1 k bases and about 1 k bases.

4. (amended) [A] The chain-shortened polynucleotide or salt thereof
according to [any one of Claims] claim 1 [to 3], wherein the polynucleotide or salt
thereof [which] is in the form of a double stranded chain-shortened polynucleotide or
salt thereof formed from two chain-shortened polynucleotides or salts thereof which are
capable of forming a double strand.

5. (amended) The double stranded chain-shortened polynucleotide or salt
thereof according to [Claim] claim 4, wherein the two chain-shortened polynucleotides
capable of forming a double strand are selected from the group consisting of
polyinosinic acid and polycytidylic acid, polyadenylic acid and polyuridylic acid,
polyinosinic acid analogue and polycytidylic acid, polyinosinic acid and polycytidylic acid
analogue, polyinosinic acid analogue and polycytidylic acid analogue, polyadenylic acid
analogue and polyuridylic acid, polyadenylic acid and polyuridylic acid analogue, and
polyadenylic acid analogue and polyuridylic acid analogue.

6. (amended) A method for preparing the chain-shortened polynucleotide
or salt thereof, [according to any one of Claims 1 to 3 characterized in that] the method
comprising reacting a polynucleotide or salt thereof [is reacted] in a solution at about pH

7 to about pH 10 and at temperature between about 20 and about 110°C to shorten the chain, thereby forming a chain-shortened polynucleotide or salt thereof, comprising phosphodiester bonds, wherein up to about 3 percent of the phosphodiester bonds are 2'-5' phosphodiester bonds.

7. (amended) A method for preparing the chain-shortened polynucleotide or salt thereof, [according to any one of Claims 1 to 3 characterized in that] the method comprising treating a polynucleotide or salt thereof [is treated] with a phosphodiesterase for chain-shortening, thereby forming a chain-shortened polynucleotide or salt thereof, comprising phosphodiester bonds, wherein up to about 3 percent of the phosphodiester bonds are 2'-5' phosphodiester bonds.

8. (amended) A composition comprising a complex formed from a carrier effective for introducing a medicament into a cell and a chain-shortened polynucleotide or salt thereof [according to any one of Claims 1 to 3 or a double stranded chain-shortened polynucleotide or salt thereof according to Claim 4 or 5] as an essential ingredient, wherein the chain-shortened polynucleotide or salt thereof comprises phosphodiester bonds, such that up to about 3 percent of the phosphodiester bonds are 2'-5' phosphodiester bonds.

9. The composition according to Claim 8, wherein the carrier effective for introducing a medicament into a cell is a positively charged carrier.

10. The composition according to Claim 9, wherein the positively charged carrier is a cationic liposome.

11. The composition according to Claim 8 wherein the carrier effective for introducing a medicament into a cell is a carrier formed from 2-O-(2-diethylaminoethyl)carbamoyl-1,3-O-dioleoyl glycerol and a phospholipid as essential constituent components.

12. (amended) The composition according to [any one of] Claim[s] 8 [to 11], wherein the composition [which] is in the form of a pharmaceutical preparation.

13. The composition according to Claim 12, wherein the pharmaceutical preparation [is] comprises an interferon inducing agent, immune activating agent, intracellular nuclease activating agent, cancer treating agent or preventive agent, or hepatitis treating agent or preventive agent.

14. (new) The method according to 6, wherein the polynucleotide is polyinosinic acid or analogue thereof, polycytidylic acid or analogue thereof, polyadenylic acid or analogue thereof, or polyuridylic acid or analogue thereof.

15. (new) The method according to claim 7, wherein the polynucleotide is polyinosinic acid or analogue thereof, polycytidylic acid or analogue thereof, polyadenylic acid or analogue thereof, or polyuridylic acid or analogue thereof.

16. (new) The composition according to claim 8, wherein the polynucleotide is polyinosinic acid or analogue thereof, polycytidylic acid or analogue thereof, polyadenylic acid or analogue thereof, or polyuridylic acid or analogue thereof.

17. (new) The composition according to claim 8, wherein the polynucleotide or salt thereof has an average chain length of between about 0.1 k bases and about 1 k bases.

18. (new) The chain-shortened polynucleotide or salt thereof according to claim 8, wherein the polynucleotide or salt thereof is in the form of a double stranded chain-shortened polynucleotide or salt thereof formed from two chain-shortened polynucleotides or salts thereof which are capable of forming a double strand.

19. (new) The double stranded chain-shortened polynucleotide or salt thereof according to Claim 18, wherein the two chain-shortened polynucleotides capable of forming a double strand are selected from the group consisting of polyinosinic acid and polycytidylic acid, polyadenylic acid and polyuridylic acid, polyinosinic acid analogue and polycytidylic acid, polyinosinic acid and polycytidylic acid analogue, polyinosinic acid analogue and polycytidylic acid analogue, polyadenylic acid analogue and polyuridylic acid, polyadenylic acid and polyuridylic acid analogue, and polyadenylic acid analogue and polyuridylic acid analogue.

The Claims:

Amend as follows:

1. (amended) A chain-shortened polynucleotide or salt thereof, comprising phosphodiester bonds, wherein up to about 3 percent of the phosphodiester bonds are 2'-5' phosphodiester bonds.

2. (amended) The chain-shortened polynucleotide or salt thereof according to claim 1, wherein the polynucleotide is polyinosinic acid or analogue thereof, polycytidylic acid or analogue thereof, polyadenylic acid or analogue thereof, or polyuridylic acid or analogue thereof.

3. (amended) The chain-shortened polynucleotide or salt thereof according to claim 1, wherein the polynucleotide or salt thereof has an average chain length of between about 0.1 k bases and about 1 k bases.

4. (amended) The chain-shortened polynucleotide or salt thereof according to claim 1, wherein the polynucleotide or salt thereof is in the form of a double stranded chain-shortened polynucleotide or salt thereof formed from two chain-shortened polynucleotides or salts thereof which are capable of forming a double strand.

5. (amended) The double stranded chain-shortened polynucleotide or salt thereof according to claim 4, wherein the two chain-shortened polynucleotides capable of forming a double strand are selected from the group consisting of polyinosinic acid and polycytidylic acid, polyadenylic acid and polyuridylic acid, polyinosinic acid analogue and polycytidylic acid, polyinosinic acid and polycytidylic acid analogue, polyinosinic acid analogue and polycytidylic acid analogue, polyadenylic acid analogue and polyuridylic acid, polyadenylic acid and polyuridylic acid analogue, and polyadenylic acid analogue and polyuridylic acid analogue.

6. (amended) A method for preparing the chain-shortened polynucleotide or salt thereof, the method comprising reacting a polynucleotide or salt thereof in a solution at about pH 7 to about pH 10 and at temperature between about 20 and about 110°C to shorten the chain, thereby forming a chain-shortened polynucleotide or salt

thereof, comprising phosphodiester bonds, wherein up to about 3 percent of the phosphodiester bonds are 2'-5' phosphodiester bonds.

7. (amended) A method for preparing the chain-shortened polynucleotide or salt thereof, the method comprising treating a polynucleotide or salt thereof with a phosphodiesterase for chain-shortening, thereby forming a chain-shortened polynucleotide or salt thereof, comprising phosphodiester bonds, wherein up to about 3 percent of the phosphodiester bonds are 2'-5' phosphodiester bonds.

8. (amended) A composition comprising a complex formed from a carrier effective for introducing a medicament into a cell and a chain-shortened polynucleotide or salt thereof as an essential ingredient, wherein the chain-shortened polynucleotide or salt thereof comprises phosphodiester bonds, such that up to about 3 percent of the phosphodiester bonds are 2'-5' phosphodiester bonds.

9. The composition according to Claim 8, wherein the carrier effective for introducing a medicament into a cell is a positively charged carrier.

10. The composition according to Claim 9, wherein the positively charged carrier is a cationic liposome.

11. The composition according to Claim 8 wherein the carrier effective for introducing a medicament into a cell is a carrier formed from 2-O-(2-diethylaminoethyl)carbonyl-1,3-O-dioleoyl glycerol and a phospholipid as essential constituent components.

12. (amended) The composition according to Claim 8, wherein the composition is in the form of a pharmaceutical preparation.

13. The composition according to Claim 12, wherein the pharmaceutical preparation comprises an interferon inducing agent, immune activating agent, intracellular nuclease activating agent, cancer treating agent or preventive agent, or hepatitis treating agent or preventive agent.

Add the following new claims:

14. (new) The method according to 6, wherein the polynucleotide is polyinosinic acid or analogue thereof, polycytidylic acid or analogue thereof, polyadenylic acid or analogue thereof, or polyuridylic acid or analogue thereof.

15. (new) The method according to claim 7, wherein the polynucleotide is polyinosinic acid or analogue thereof, polycytidylic acid or analogue thereof, polyadenylic acid or analogue thereof, or polyuridylic acid or analogue thereof.

16. (new) The composition according to claim 8, wherein the polynucleotide is polyinosinic acid or analogue thereof, polycytidylic acid or analogue thereof, polyadenylic acid or analogue thereof, or polyuridylic acid or analogue thereof.

17. (new) The composition according to claim 8, wherein the polynucleotide or salt thereof has an average chain length of between about 0.1 k bases and about 1 k bases.

18. (new) The chain-shortened polynucleotide or salt thereof according to claim 8, wherein the polynucleotide or salt thereof is in the form of a double stranded chain-shortened polynucleotide or salt thereof formed from two chain-shortened polynucleotides or salts thereof which are capable of forming a double strand.

19. (new) The double stranded chain-shortened polynucleotide or salt thereof according to Claim 18, wherein the two chain-shortened polynucleotides capable of forming a double strand are selected from the group consisting of polyinosinic acid and polycytidylic acid, polyadenylic acid and polyuridylic acid, polyinosinic acid analogue and polycytidylic acid, polyinosinic acid and polycytidylic acid analogue, polyinosinic acid analogue and polycytidylic acid analogue, polyadenylic acid analogue and polyuridylic acid, polyadenylic acid and polyuridylic acid analogue, and polyadenylic acid analogue and polyuridylic acid analogue.

DESCRIPTION

CHAIN-SHORTENED POLYNUCLEOTIDE
AND METHOD FOR PREPARATION THEREOF

5

TECHNICAL FIELD

The present invention relates to a chain-shortened polynucleotide particularly useful as a medicine, and a method for preparing the same. More specifically, the present invention relates

10 to a synthetic chain-shortened polynucleotide or salts thereof, wherein the proportion of a 2'-5' phosphodiester bond is up to 3% based on the whole phosphodiester bonds, i.e., the rate of phosphate groups rearranged from 3' position to 2' position based on the whole phosphate groups of phosphodiester bonds (the phosphate

15 rearrangement rate) is up to 3%, and a method for preparing the same.

TECHNICAL BACKGROUND

Polynucleotides typified by polyinosinic - polycytidylic acid, i.e., poly(I)·poly(C), are well-known compounds in the art, and the

20 potentiality as a medicine for treating hepatitis or cancer have been investigated in view of their interferon inducing action, immune activating action, and the like.

The pharmacological action of these polynucleotides has high correlation with the chain length, and longer the chain length,

25 stronger the interferon inducing action and the like. On the other hand, longer the chain length, stronger the toxicity manifested.

Recently, there has been an approach for reducing toxicity with maintaining useful pharmacological action of a polynucleotide, by a method wherein a synthetic polynucleotide having a relatively

shorter chain prepared by the hydrolysis of a polynucleotide is enclosed in a carrier such as cationic liposome effective for introducing a medicament into a cell (e.g., PCT WO99/20283, PCT WO99/48531).

It is known that when a polynucleotide is hydrolyzed to shorten the chain length as described above, some phosphate groups cause intramolecular rearrangement from 3' position to 2' position through a mechanism called pseudo rotation simultaneously with the chain-shortening (see, e.g., "Protein Nucleic acid Enzyme", Vol. 40, No. 10, pp. 1323 to 1332 (1995)). As a result, a portion of 3'-5' phosphodiester bonds in the chain-shortened polynucleotide molecule are replaced by 2'-5' phosphodiester bonds. It has never been known whether or not such a phosphate rearrangement phenomenon would affect the pharmacological action.

DESCRIPTION OF INVENTION

An object of the present invention is to provide, firstly, a chain-shortened polynucleotide or salt thereof and a double stranded chain-shortened polynucleotide or salt thereof, which are safe and effective as a medicine.

The present inventors have been intensively studied and found that the problems described above can be solved by a chain-shortened polynucleotide which contains 2'-5' phosphodiester bond produced mainly in a chain-shortening reaction only at a particular proportion or less, or a salt thereof, and accomplished the present invention.

An aspect of the present invention is a chain-shortened polynucleotide containing a 2'-5' phosphodiester bond at a proportion of 3% or less, preferably 2% or less, based on the whole

phosphodiester bonds, or salt thereof.

The present invention includes also as an embodiment a double stranded chain-shortened polynucleotide or salt thereof, which is formed from two chain-shortened polynucleotides or salts thereof capable of forming a double strand, which is inclusive in the above-described chain-shortened polynucleotides containing a 2'-5' phosphodiester bond at a proportion of 3% or less, preferably 2% or less, based on the whole phosphodiester bonds. Further, the present invention also includes a composition comprising a complex formed from a carrier effective for introducing a medicament into a cell and the above-described chain-shortened polynucleotide or salt thereof wherein the proportion of a 2'-5' phosphodiester bond is 3% or less based on the whole phosphodiester bonds, or the double stranded chain-shortened polynucleotide or salt thereof formed from two chain-shortened polynucleotides or salts thereof capable of forming a double strand as an essential ingredient.

The polynucleotide used in the present invention is a compound comprising at least about 20 nucleotides, which is formed by polymerizing linearly through a phosphodiester bond and includes synthetic and natural compounds. Specific examples include polyinosinic acid [namely, poly(I)] or an analogue thereof, polycytidylic acid [namely, poly(C)] or an analogue thereof, polyadenylic acid [namely, poly(A)] or an analogue thereof, and polyuridylic acid [namely, poly(U)] or an analogue thereof.

The polyinosinic acid analogue is a homopolymer in which all or a part of inosinic acid is chemically modified or a copolymer of inosinic acid with other nucleotide, for example, poly(7-deazainosinic acid) and poly(2'-azidoinosinic acid). The polycytidylic acid analogue is a homopolymer in which all or a part of cytidylic acid is chemically

modified or a copolymer of cytidylic acid with other nucleotide, for example, poly(5-bromocytidylic acid), poly(2-thiocytidylic acid), poly(cytidine-5'-thiophosphoric acid), poly(cytidylic acid, uridylic acid), poly(cytidylic acid, 4-thiouridylic acid) and poly(1-vinylcytidylic acid). The polyadenylic acid analogue and polyuridylic acid analogue are defined likewise. Among them, polyinosinic acid and polycytidylic acid are suitable in the present invention.

The average chain length of the chain-shortened polynucleotide of the present invention is suitably from 0.1 k bases to 1 k base. The term "base" means the number of base and "1 k base" indicates a base number of 1000, and hereinafter, "base(s)" is abbreviated to "b". The mean chain length is preferably from 200 b to 800 b, and more preferably from 300 b to 600 b. The average chain length can be determined easily, for example, by gel permeation chromatography (hereinafter, referred to as "GPC") as described hereinafter in Experiment 5.

In the chain-shortened polynucleotide of the present invention, the phosphate rearrangement rate is 3 % or less, preferably 2% or less or between 0.1% and 2%, and more preferably 1% or less or between 0.1% and 1%.

The rearrangement of phosphate group from 3' position to 2' position in polynucleotide can be confirmed easily, for example, by a method as described in Experiment 6. Namely, a polynucleotide is degraded with nuclease P_1 , which specifically hydrolyzes a 3'-5' phosphodiester bond to such levels as a nucleoside, nucleotide and oligonucleotide, and then treated with an alkaline phosphatase, which specifically hydrolyzes a terminal phosphate group, to convert the whole nucleotides into nucleosides. On the other hand, an oligonucleotide having a 2'-5' phosphodiester bond, which is not

hydrolyzed by the nuclease P_1 is not degraded till nucleoside even by the treatment with an alkaline phosphatase because an intramolecular 2'-5' phosphodiester bond is not hydrolyzed. The phosphate rearrangement rate can be calculated by determining
 5 nucleosides and oligonucleotides (most of them are dimers) by liquid chromatography, or the like.

Examples of a pair of chain-shortened polynucleotides capable of forming a double strand in connection with the present invention include polyinosinic acid and polycytidylic acid,
 10 polyadenylic acid and polyuridylic acid, polyinosinic acid analogue and polycytidylic acid, polyinosinic acid and polycytidylic acid analogue, polyinosinic acid analogue and polycytidylic acid analogue, polyadenylic acid analogue and polyuridylic acid, polyadenylic acid and polyuridylic acid analogue, and polyadenylic acid analogue and
 15 polyuridylic acid analogue. Therefore, examples of the double stranded chain-shortened polynucleotide formed between two chain-shortened polynucleotides capable of forming a double strand include polyinosinic - polycytidylic acid, polyadenylic - polyuridylic acid, polyinosinic analogue - polycytidylic acid, polyinosinic - polycytidylic
 20 acid analogue, polyinosinic analogue - polycytidylic acid analogue, polyadenylic analogue - polyuridylic acid, polyadenylic - polyuridylic acid analogue, and polyadenylic analogue - polyuridylic acid analogue.


For the purposes of the present invention, polyinosinic - polycytidylic acid would be a preferred double stranded chain-
 25 shortened polynucleotide.

The average chain length of the above-described double stranded chain-shortened polynucleotide is reasonably regarded as corresponding to the average chain length of the whole chain-shortened polynucleotides. Accordingly, the latter can be used to

show the apparent average chain length of the double stranded chain-shortened polynucleotide in terms of the number of base pairs (bp). Therefore, the average chain length of the above-described double stranded chain-shortened polynucleotide is from 0.1 k bp to 1 k bp. The term "bp" means the number of base pairs and "1 k bp" corresponds to a base pair number of 1000. The average chain length of the double-stranded polynucleotide is preferably from 200 bp to 800 bp, and more preferably from 300 bp to 600 bp.

The salt of a chain-shortened polynucleotide and that of a double stranded chain-shortened polynucleotide of the present invention are not particularly restricted as far as they are pharmaceutically acceptable, and examples thereof include a sodium salt and potassium salt.

As a carrier effective for introducing a medicament into a cell, those having a positive charge are exemplified, and specific examples include cationic polymers such as poly-L-lysine, cationic liposomes such as Lipofectin®, Lipofectamine®, Lipofectace®, DMRIE-C®, etc., and carriers considered to be of the same kind which are disclosed in PCT WO94/19314. The carriers for carrying a medicament are formed, for example, from 2-O-(2-diethylaminoethyl)carbamoyl-1,3-O-dioleoyl glycerol of the formula [I]:



and a phospholipid (e.g., phosphatidyl choline, phosphatidyl ethanolamine, yolk lecithin, soy bean lecithin, hydrogenated phospholipid thereof) as essential structural components.

It is believed that the above-described cationic liposome is positively charged and forms an electrostatic complex with a negatively charged polynucleotide or oligonucleotide. When the resultant complex fuses with cell membrane, the polynucleotide or oligonucleotide is concurrently introduced into the cell. Such a complex is sometimes called "lipoplex".

A method for preparing the chain-shortened polynucleotide of the present invention will be described in detail. The chain-shortened polynucleotide of the present invention can be prepared, for example, by hydrolyzing the starting polynucleotide in solution at suitable pH range while heating at a suitable temperature range. The suitable pH of the aqueous solution in this procedure is basic, i.e., pH 7 or more, preferably pH 7 to 10. Considering the reaction rate of the chain-shortening reaction and the stability of base moiety, more preferable pH of the solution would be between 8 and 9. The reaction temperature is suitably within a range of 20 to 110°C, preferably 40 to 100°C, from the standpoint of the stability of a base. However, considering the sufficient hydrolysis rate and the stability of base moiety, more preferable reaction temperature would be between 50 and 90°C.

More specifically, for example, a polynucleotide is dissolved in water such as injectable water, distilled water for injection or physiological saline with stirring, and pH of the solution is adjusted to 8 to 9 with a buffer or a pH regulator. When the hydrolysis is conducted by heating the solution at reaction temperature ranging from 50 to 90°C for 0.5 to 60 hours while monitoring the average chain length and the phosphate rearrangement rate, a chain-shortened polynucleotide containing less phosphate groups rearranged and having an average chain length between 0.1 kb and 1 kb can be

produced.

Pharmaceutically acceptable additives such as a buffer or a pH regulator may be used for adjusting pH. Specific examples include buffers and pH regulators such as aminoacetic acid (synonym: glycine), tris(hydroxymethyl)aminomethane (synonym: Tris), sodium carbonate, sodium hydrogen carbonate (synonym: sodium bicarbonate), sodium hydroxide, diethanolamine, triethanolamine and the like. There are no limitations regarding the kind, combination, concentration and the like of these additives.

10 Monomers and unnecessary salts, impurities, by-products produced during the chain-shortening reaction and the like can be removed from the system by treating the reaction solution by dialysis or with activated carbon.

The chain-shortened polynucleotide of the present invention
15 can also be prepared by treating the starting polynucleotide in solution with a phosphodiesterase at suitable pH range while heating at a suitable temperature range. The suitable pH of the aqueous solution in this procedure is between 4 and 9, preferably, between 5 and 8. Considering the phosphate rearrangement during the chain-
20 shortening reaction, more preferable pH of the solution would be between 6 and 7. The reaction temperature is suitably within a range of 20 to 60°C, preferably 25 to 50°C, from the standpoint of the characteristics of the enzyme. However, more preferable reaction temperature would be between 30 and 40°C taking the sufficient
25 hydrolysis rate, the avoidance of influence of non-enzymatic hydrolysis such as hydrolysis with heat, and the prevention of phosphate-group rearrangement into consideration.

More specifically, for example, a polynucleotide is dissolved in water such as injectable water, distilled water for injection or

physiological saline with stirring. The pH of the solution is optionally adjusted by adding a buffer or a pH regulator, if necessary. To the solution is added phosphodiesterase such as nuclease P_1 and the resultant mixture is subjected to the chain-shortening reaction at temperature from 30 to 40°C while monitoring the average chain length and phosphate rearrangement rate to obtain a chain-shortened polynucleotide containing less phosphate groups rearranged and having an average chain length between 0.1 kb and 1 kb. There are no limitations regarding the enzyme concentration or reaction conditions.

Monomers and unnecessary salts, impurities, by-products produced during the chain-shortening reaction and the like can be removed from the system by treating the reaction solution by the ethanol precipitation method, dialysis or with activated carbon.

The chain-shortened polynucleotide can be purified by an appropriate separation method with a membrane. For example, membrane ultrafiltration is suited for the purpose of fractionating polynucleotides of average chain length between 0.1 kb and 1 kb of the present invention. There are no limitations regarding the quality of material or the pore size of the membrane.

As a starting material, any polynucleotides can be used regardless of origin such as natural or synthetic, the kind of salt or the chain length. Examples of natural polynucleotide include tRNA and polyadenylic acid. On the other hand, a synthetic polynucleotide can be produced from an RNA synthetase such as polynucleotide phosphorylase or immobilized enzymes thereof. Further, sodium polyinosinate, sodium polycytidylate, etc., which are commercially available as interferon inducing reagents, are also usable as a starting material.

The double stranded chain-shortened polynucleotide of the present invention can be prepared by mixing, in a suitable solution (for example, 0.15 M NaCl-containing 10 mM Tris-hydrochloric acid buffer (Tris-HCl buffer, pH7)), two chain-shortened polynucleotides
5 capable of forming a double strand among chain-shortened polynucleotides containing less phosphate groups rearranged as prepared in the above, or alternatively, by allowing them to anneal in a conventional manner. As the annealing method, there is, for example, a method in which a solution containing two chain-
10 shortened polynucleotides capable of forming a double strand is heated up to 70 to 80°C, and then cooled gradually.

A chain-shortened polynucleotide with less phosphate groups rearranged or a double stranded chain-shortened polynucleotide with less phosphate groups rearranged obtained as described above can be
15 treated by lyophilization to give a lyophilized product storable for a long period. The lyophilization treatment can be conducted in a conventional manner. For example, a lyophilized product can be obtained as follows: a solution of a chain-shortened polynucleotide obtained under the conditions above is sterilized by filtration, the
20 filtrate is then poured on a metal bat previously treated by dry heat sterilization, a pre-freezing is conducted at a shelf temperature from -40 to -20°C for about 1 to 4 hours, and primary drying is conducted before the secondary drying which is effected under reduced pressure at a shelf temperature from 15 to 30°C (for about 10 to 50 hours).
25 Generally, such a lyophilized product can be used after reconstitution (re-dissolution) by the addition of an appropriate solution such as injectable water, distilled water for injection, physiological saline, maltose solution, glucose solution, or the like.

The composition of the present invention can be prepared in a

manner similar to those generally used for the preparation of liposome, which composition comprises a complex (hereinafter, referred to as the present complex) formed with a carrier effective for introducing a medicament into a cell and a two chain-shortened polynucleotide containing 2'-5' phosphodiester bonds at proportion of 3% or less based on the whole phosphodiester bonds and being capable of forming a double strand, or a double-stranded chain-shortened polynucleotide formed between the said two chain-shortened polynucleotides capable of forming a double strand as an essential ingredient. Specifically, a composition for injection of the present invention can be prepared by the following steps comprising adding water (injectable water, distilled water for injection, physiological saline and the like) to a carrier effective for introducing a medicament into a cell, for example, a cationic liposome or raw material thereof (e.g., glycerol derivative such as 2-O-(2-diethylaminoethyl)carbamoyl-1,3-O-dioleoyl glycerol and the like and phospholipid); stirring the mixture; treating the mixture with a suitable device for dispersion, for example, a homomixer, a homogenizer, a ultrasonic dispersing device, a ultrasonic homogenizer, a high pressure emulsifying dispersing device, Microfluidizer (trade name), Nanomizer (trade name), De Bee 2000 (trade name), Ultimixer (trade name) or Manton-Gaulin type high pressure homogenizer; adding a chain-shortened polynucleotide or a double stranded chain-shortened polynucleotide of the present invention to the resultant lipid dispersion; re-dispersing the mixture by treating with a suitable dispersing device; and then subjecting the resultant composition to sterilization by filtration or the like. Any other additives can be added at an appropriate step during the preparation without any particular limitation. Alternatively, a composition of the present invention containing the present complex

can be prepared as follows. Thus, a mixture of a carrier effective for introducing a medicament into a cell, for example, a cationic liposome or raw material thereof (e.g., glycerol derivative such as 2-O-(2-diethylaminoethyl)carbamoyl-1,3-O-dioleoyl glycerol and the like and phospholipid) and a chain-shortened polynucleotide or a double stranded chain-shortened polynucleotide of the present invention is first prepared. To the previously prepared mixture is added water while conducting the dispersion treatment at the same time. Further, a composition of the present invention can also be prepared via a suitable crude dispersing step during the above-described methods.

The resultant composition of the present invention can be lyophilized, whereby a lyophilized preparation of a composition of the present invention storable for a long period is obtained. The lyophilization can be conducted in a conventional manner. For example, a given amount of a composition of the present invention, which has been obtained by the above-mentioned dispersion and sterilization by filtration, is dispensed into a vial. The lyophilization is carried out by subjecting the vial to pre-freezing at a temperature between about -40 and -20°C for about 2 to 3 hours, the primary drying at a temperature between about 0 and 10°C under reduced pressure, and the secondary drying at a temperature between about 15 and 25°C under reduced pressure. Generally, after replacing the inner space with an inert gas such as nitrogen gas, the vial is capped to provide a lyophilized preparation of a composition of the present invention.

The lyophilized preparation of a composition of the present invention can be used after reconstitution by adding an appropriate solution before use. Examples of such a solution for reconstitution include injectable water, distilled water for injection, physiological

saline, maltose solution, glucose solution and other general infusion solutions and the like.

The composition of the present invention and lyophilized preparation thereof can be used in the form of a pharmaceutical
 5 preparation as a medicine. The composition of the present invention and lyophilized preparation as a medicine exhibits a pharmacological activity owing to the active polynucleotide. The specific examples of the medicine include interferon inducing agents, immune activating agents, intracellular nuclease activating agents,
 10 cancer treating or preventive agents, and hepatitis treating or preventive agents.

BEST MODE FOR CARRYING OUT THE PRESENT INVENTION

The following examples and experiments further illustrate the
 15 present invention in more detail. The present invention is not restricted by these examples and experiments at all.

REFERENCE EXAMPLE 1

To 8 g of trisodium inosine-5'-diphosphate and 1 g of magnesium chloride was added 500 mL of a 0.1 M glycine-sodium
 20 hydroxide buffer, and the mixture was stirred for dissolution. After the pH was adjusted to 9.3 by the addition of 6N sodium hydroxide, the mixture was allowed to stand for 1 hour at 38°C. To the mixture was added 1 mL of a polynucleotide phosphorylase solution, and the reaction was conducted at 38°C for 18 hours. After the reaction was
 25 quenched by adding 25 mL of 0.2 M ethylenediaminetetraacetic acid (EDTA), 10 mL of saturated saline and 500 mL of absolute ethanol were added to precipitate polyinosinic acid (1973b).

REFERENCE EXAMPLE 2

To 10 g of trisodium cytidine-5'-diphosphate and 3 g of

manganese chloride was added about 1 L of a 0.2 M sodium hydrogen carbonate-sodium hydroxide buffer, and the mixture was stirred for dissolution. After the pH was adjusted to 9.8 by the addition of 6N sodium hydroxide, the mixture was allowed to stand for about 1 hour at 36°C. To the mixture was added 2 mL of a purified polynucleotide phosphorylase solution, and the reaction was conducted at 36°C for 24 hours. The reaction was quenched by adding 50 mL of 0.2 M EDTA. To the mixture were then added 20 mL of saturated saline and 1 L of absolute ethanol to precipitate polycytidylic acid (3300 b).

EXAMPLE 1

Polyinosinic acid obtained in Reference Example 1 was separated by centrifugation. The precipitate was re-dissolved in 500 mL of injectable water and subjected to dialysis. The inner solution after dialysis was treated with an activated carbon and filtrated to remove the activated carbon. To filtrate was added 6N sodium hydroxide to adjust to pH 8.5. The hydrolysis was conducted by heating at 70°C for 8 hours to shorten the chain of polyinosinic acid. The resultant solution of chain-shortened polynucleotide was treated with an activated carbon, filtrated to remove the activated carbon, and dialyzed. The inner solution after dialysis was sterilized by filtration. The filtrate was subjected to lyophilization in a conventional manner to obtain 1.9 g of a lyophilized product of chain-shortened polynucleotide (polyinosinate, sodium salt) of the present invention with less phosphate groups rearranged (phosphate rearrangement rate: 0.2%, average chain length: 360 b).

EXAMPLE 2

Polycytidylic acid obtained in Reference Example 2 was separated by centrifugation. The precipitate was re-dissolved in 500 mL of injectable water and subjected to dialysis. The inner solution

after dialysis was treated with an activated carbon and filtered to remove the activated carbon. To filtrate was added 6N sodium hydroxide to adjust pH to 9.0. The hydrolysis was conducted by heating at 80°C for 4 hours to shorten the chain of polycytidylic acid.

- 5 The resultant solution of chain-shortened polynucleotide was treated with an activated carbon, filtrated to remove the activated carbon, and dialyzed. The inner solution after dialysis was sterilized by filtration. The filtrate was lyophilized in a conventional manner to obtain 2.7 g of a lyophilized product of chain-shortened polynucleotide
- 10 (polycytidylate, sodium salt) of the present invention with less phosphate groups rearranged (phosphate rearrangement rate: 0.1%, average chain length: 318 b).

EXAMPLE 3

- To 1 g of sodium polyadenylate ($S_{20,w}^0$ (sedimentation constant): 7.2, Seikagaku Corporation) was added 200 mL of 0.1 M Tris-HCl buffer (pH 8.0), and the mixture was stirred for dissolution. Hydrolysis was conducted by heating at 60°C for 48 hours to shorten the chain of polyadenylic acid while monitoring the average chain length according to the method described in Experiment 5. The
- 15 solution of chain-shortened polynucleotide was subjected to dialysis. The inner solution after dialysis was subjected to lyophilization in a conventional manner to obtain 0.3 g of a lyophilized product of chain-shortened polynucleotide (polyadenylate, sodium salt) of the present invention with less phosphate groups rearranged (phosphate
- 20 rearrangement rate: 1.9%, average chain length: 154 b).

EXAMPLE 4

To 1 g of sodium polyuridylylate ($S_{20,w}^0$ (sedimentation constant): 6.5, Seikagaku Corporation) was added 200 mL of 0.2 M glycine-NaOH buffer (pH 9.0), and the mixture was stirred for

- dissolution . Hydrolysis was conducted by heating at 60°C for 25 hours to shorten the chain of the polyadenylic acid while monitoring the average chain length according to the method described in Experiment 5. The resultant solution of chain-shortened polynucleotide was subjected to dialysis. The inner solution of the dialysis was subjected to lyophilization in a conventional manner to obtain 0.2 g of a lyophilized product of chain-shortened polynucleotide (polyuridylylate, sodium salt) of the present invention with less phosphate groups rearranged (phosphate rearrangement rate: 1.2%, average chain length: 108 b).

Example 5

- To 250 mg of sodium polyinosinate ($S^{\circ}_{20,w}$ (sedimentation constant): 8.8, Yamasa Corporation) was added 50 mL of 0.1 M Tris-HCl buffer (pH 8.0), and the mixture was stirred for dissolution . The solution was heated at a temperature from 50 to 120°C suitable for chain-shortening. Polyinosinic acids having an arbitrary chain length were sampled while monitoring the average molecular length by the method described in Experiment 5. The results are shown in Table 1. The resultant sample solutions were dialyzed, and lyophilized in a conventional manner to obtain lyophilized products.

Table 1

Temperature for chain-shortening reaction	Time for chain-shortening reaction	Average chain length	Phosphate rearrangement rate
50 °C	50 hours	1419 b	0.1%
60 °C	27 hours	982 b	0.1%
70 °C	12 hours	524 b	0.4%
80 °C	8 hours	118 b	1.2%
90 °C	3 hours	84 b	1.8%
120 °C	1 hour	32 b	6.8%

EXAMPLE 6

To 250 mg of sodium polycytidylate ($S_{20,w}^0$ (sedimentation constant): 8.6, Yamasa Corporation) was added 50 mL of 0.1 M Tris-HCl buffer (pH 9.0), and the mixture was stirred for dissolution. The solution was heated at a temperature from 55 to 120°C suitable for chain-shortening. Polycytidylic acids having an arbitrary chain length were sampled while monitoring the average molecular length by the method described in Experiment 5. The results are shown in Table 2. The resultant sample solutions were dialyzed, and lyophilized in a conventional manner to obtain lyophilized products.

Table 2

Temperature for chain-shortening reaction	Time for chain-shortening reaction	Average chain length	Phosphate rearrangement rate
55 °C	52 hours	1923 b	0.1%
65 °C	48 hours	907 b	0.1%
75 °C	23 hours	489 b	0.3%
80 °C	12 hours	139 b	0.8%
90 °C	8 hours	76 b	1.2%
120 °C	1.5 hours	27 b	4.2%

It is apparent from the results obtained in Examples 5 and 6 that, in the chain-shortening process of commercially available sodium polyinosinate or sodium polycytidylate, sufficient hydrolysis could not be achieved when the chain-shortening was carried out at 55°C or below. As a result, the average chain length exceeded 1 kb even after about 50 hours of chain shortening reaction. On the other hand, in samples wherein the chain-shortening was carried out at 120°C or 90°C, the control of the chain-shortening was difficult because of too fast hydrolysis rate. Particularly, in the sample wherein the chain shortening was carried out at 120°C, the chain was too much shortened to such an extent of around oligonucleotide level

even after 1 to 1.5 hours of chain-shortening. In this sample, the phosphate rearrangement rate was high and degradation of base moiety was also recognized.

EXAMPLE 7

- 5 One hundred mg of sodium polyadenylate ($S^{\circ}_{20,w}$ (sedimentation constant): 7.2, Seikagaku Corporation) was dissolved in 100 mL of 0.1 M Tris-HCl buffer (pH 7.0). To the solution was added nuclease P_1 (derived from *Penicillium citrinum*, Seikagaku Corporation). The mixture was incubated at 25 °C for 3 hours while
- 10 monitoring the average chain length according to the method described in Experiment 5 to shorten the chain of polyadenylic acid (phosphate rearrangement rate: 0.1%, average chain length: 287 b).

EXAMPLE 8

- To 1 g of trisodium uridine-5'-diphosphate and 0.3 g of
- 15 magnesium chloride was added 100 mL of a 0.2 M sodium hydrogencarbonate-sodium hydroxide buffer, and the mixture was stirred for dissolution. After adjusting pH to 9.5 with 1N sodium hydroxide, 0.2 mL of polynucleotide phosphorylase was added. The mixture was then allowed to react for 10 hours at 25°C while
- 20 monitoring the average chain length according to the method described in Experiment 5. After the reaction was quenched by adding 5 mL of 0.2 M EDTA, 2 mL of saturated saline and 100 mL of ethanol were added to precipitate polyuridylic acid (549b). The polyuridylic acid was separated by centrifugation. The precipitate
- 25 was re-dissolved in 50 ml of injectable water and dialyzed. The inner solution of the dialysis was adjusted to pH 8.5 with 1N sodium hydroxide and hydrolyzed at 80°C for 30 minutes to regulate the chain length of polyuridylic acid. The resultant solution of chain-shortened polynucleotide was subjected to membrane separation by

ultrafiltration so as to adjust the chain-length distribution, as well as to remove the unnecessary salt, by-products during the chain-shortening reaction or the like (phosphate rearrangement rate: 0.1%, average chain length: 485 b).

5 EXAMPLE 9

To 1 g of 2-O-(2-diethylaminoethyl)carbamoyl-1,3-O-dioleoyl glycerol and 2 g of purified yolk lecithin was added 40 g of maltose dissolved in 100 mL of injectable water. The mixture was stirred and dispersed for 5 minutes with a homogenizer to obtain a crude
10 dispersion of a cationic liposome (carrier). The crude dispersion was further dispersed for 1 hour with a laboratory small emulsifying dispersing device to obtain a cationic liposome solution. To the cationic liposome solution was added gradually about 50 mL of an aqueous solution containing 200 mg each of the chain-shortened
15 sodium polyinosinate and sodium polycytidylate each containing less phosphate groups rearranged, which were obtained in Examples 1 and 2, with stirring. The mixture was then treated with a laboratory small emulsifying dispersing device for another 2 hours, and finally adjusted the volume to 400 mL with injectable water to obtain a
20 composition containing the present complex. The composition containing the present complex was sterilized by filtration, dispensed in 1 ml aliquots into a vial, and converted into a lyophilized preparation in a conventional manner. When the lyophilized preparation was reconstituted by the addition of injectable water to
25 make the volume 1 ml, the average particle diameter of the present complex was 133 nm when evaluated by the photon correlation method.

EXAMPLE 10

To 50 g of 2-O-(2-diethylaminoethyl)carbamoyl-1,3-O-dioleoyl

glycerol and 25 g of soy bean lecithin was added 1 kg of sucrose dissolved in 3 L of injectable water. The mixture was stirred and dispersed for 30 minutes with a Manton-Gaulin type high pressure homogenizer, and the volume was adjusted to 5 L with injectable

5 water to obtain a dispersion of a cationic liposome (carrier). To the carrier dispersion was added about 2 L of an aqueous solution containing 1 g each of the chain-shortened sodium polyinosinate and sodium polycytidylate each containing less phosphate groups rearranged, which were obtained in Examples 1 and 2, with stirring.

10 The dispersion was adjusted to pH 5.5 with 1N hydrochloric acid and dispersed with a Manton-Gaulin type high pressure homogenizer for another 1 hour, and finally the volume was adjusted to 10 L with injectable water to obtain a composition containing the present complex. The composition containing the present complex was then

15 dispensed in 20 mL aliquots into a vial and converted into a lyophilized preparation in a conventional manner. When the lyophilized preparation was reconstituted by the addition of injectable water to make the volume 20 ml, the average particle diameter of the present complex was 158 nm when evaluated by the photon

20 correlation method.

EXAMPLE 11

To 1 g of 2-O-(2-diethylaminoethyl)carbamoyl-1,3-O-dioleoyl glycerol and 2 g of yolk phosphatide was added 40 g of glucose dissolved in 100 mL of injectable water. The mixture was stirred and

25 dispersed for 5 minutes with a homogenizer, and the volume was adjusted to 500 mL to obtain a crude dispersion of a cationic liposome (carrier). The crude dispersion was further dispersed for 1 hour with a laboratory small emulsifying dispersing device to obtain a cationic liposome solution. The solution was dispensed in 10 mL aliquots

into a vial and lyophilized in a conventional manner. To the lyophilized product was added 10 mL of an aqueous solution containing 5 mg each of the chain-shortened sodium polyinosinate, sodium polycytidylate each containing less phosphate groups rearranged, which were obtained in Examples 1, 2 or 5, 6, and 5 mg each of the commercially available sodium polyinosinate ($S^{\circ}_{20,w}$ (sedimentation constant): 8.8, Yamasa Corporation) and sodium polycytidylate ($S^{\circ}_{20,w}$ (sedimentation constant): 8.6, Yamasa Corporation). The mixture was subjected to the dispersion treatment for 10 minutes with a probe type ultrasonic dispersing device to obtain a composition containing the present complex.

EXAMPLE 12

An aqueous solution (1 mL) containing 100 μ g each of the chain-shortened sodium polyadenylate and sodium polyuridylylate each containing less phosphate groups rearranged, which were obtained in Examples 3 and 4, and 2 mL of an aqueous solution containing 2 mg of a commercially available Lipofectin (trade name) were mixed with stirring. The mixture was dispersed for 15 minutes with a probe type ultrasonic dispersing device to obtain a composition containing the present complex.

EXAMPLE 13

To about 200 mg of sodium polyinosinate ($S^{\circ}_{20,w}$ (sedimentation constant): 8.8, Yamasa Corporation) was added 0.2 M acetic acid-sodium acetate buffer (pH 5.2), and the mixture was stirred for dissolution. The mixture was heated at 80°C and polyinosinic acids having an arbitrary phosphate rearrangement rate were sampled while monitoring the phosphate rearrangement rate by the method described in Experiment 6. Polyinosinic acid of each phosphate rearrangement rate was heated at 60°C in a borate buffer

(pH 8.5) to shorten the chain length until the average chain length became 200 ± 50 b while monitoring the chain length according to the method described in Experiment 5. The results are shown in Table 3.

- 5 The respective chain-shortened polyinosinic acid solutions so obtained were dialyzed and lyophilized in a conventional manner to obtain a lyophilized product.

Table 3

Rearrangement reaction		Chain-shortening reaction			
Temp.	Time (hour)	Temp.	Time (hour)	Average chain length	Phosphate rearrangement rate
80°C	2.5	60°C	3	227 b	0.7 %
	6.5		1.5	230 b	2.0 %
	9		4	191 b	2.8 %
	16.5		2	228 b	4.2 %

10 EXAMPLE 14

- To about 200 mg of sodium polycytidylate ($S^{\circ}_{20,w}$ (sedimentation constant): 8.6, Yamasa Corporation) was added 0.2 M acetic acid-sodium acetate buffer (pH 5.2), and the mixture was stirred for dissolution. The mixture was heated at 80°C and
- 15 polycytidylic acids having an arbitrary phosphate rearrangement rate were sampled while monitoring the phosphate rearrangement rate by the method described in Experiment 6. Polycytidylic acid of each phosphate rearrangement rate was heated at 70°C in a borate buffer (pH 8.5) to shorten the chain length until the average chain length
- 20 became 200 ± 50 b while monitoring the chain length according to the method described in Experiment 5. The results are shown in Table 4.
- The respective chain-shortened polyinosinic acid solutions so obtained were dialyzed and lyophilized in a conventional manner to obtain a lyophilized product.

Table 4

Rearrangement reaction		Chain-shortening reaction			
Temp.	Time (hour)	Temp.	Time (hour)	Average chain length	Phosphate rearrangement rate
80°C	3	70°C	3	157 b	1.2 %
	4.5		1	218 b	1.9 %
	6		1	236 b	2.7 %
	10	not-adjusted		170 b	3.8 %

EXAMPLE 15 Double Stranded Chain-shortened Polynucleotide

Double stranded chain-shortened polynucleotides (double stranded RNAs) were prepared from the following combinations: polyinosinic acid (phosphate rearrangement rate: 0.7%) and polycytidylic acid (phosphate rearrangement rate: 1.2%); polyinosinic acid (phosphate rearrangement rate: 2.0%) and polycytidylic acid (phosphate rearrangement rate: 1.9%); polyinosinic acid (phosphate rearrangement rate: 2.8%) and polycytidylic acid (phosphate rearrangement rate: 2.7%), which have been obtained according to the method of Example 1, 2, 11 or 12. Each double stranded chain-shortened polynucleotides was prepared by dissolving sodium polyinosinate and sodium polycytidylate into Tris-HCl buffer (pH 7, containing 0.15 M NaCl), heating the solution at 80°C for 5 minutes, and gradually cooling the solution.

COMPARATIVE EXAMPLE 1

This comparative example corresponds to Example 1 above, wherein the preparation is conducted by a conventional method (preparation-1).

To 5 mg of sodium polyinosinate ($S_{20,w}^0$ (sedimentation constant): 8.8, Yamasa Corporation) was added 10 mL of injectable water, and the mixture was stirred for dissolution. To the solution

was added 10 mL of formamide, and the mixture was heated at 80°C for 5 hours (phosphate rearrangement rate: 8.9%, average chain length: 628b).

COMPARATIVE EXAMPLE 2

5 This comparative example corresponds to Example 2 above, wherein the preparation is conducted by a conventional method (preparation-1).

To 5 mg of sodium polycytidylate ($S_{20,w}^0$ (sedimentation constant): 8.6, Yamasa Corporation) was added 10 mL of injectable
10 water, and the mixture was stirred for dissolution. To the solution was added 10 mL of formamide, and the mixture was heated at 80°C for 5 hours (phosphate rearrangement rate: 4.2%, average chain length: 751b).

COMPARATIVE EXAMPLE 3

15 This comparative example corresponds to Example 1 above, wherein the preparation is conducted by a conventional method (preparation-2).

To 5 mg of sodium polyinosinate ($S_{20,w}^0$ (sedimentation constant): 8.8, Yamasa Corporation) was added 10 mL of injectable
20 water, and the mixture was stirred for dissolution. The solution was heated at 90°C for 8 hours (phosphate rearrangement rate: 7.1%, average chain length: 213 b).

COMPARATIVE EXAMPLE 4

This comparative example corresponds to Example 2 above,
25 wherein the preparation is conducted by a conventional method (preparation-2).

To 5 mg of sodium polycytidylate ($S_{20,w}^0$ (sedimentation constant): 8.6, Yamasa Corporation) was added 10 mL of injectable water, and the mixture was stirred for dissolution. This solution

was heated at 90°C for 12 hours (phosphate rearrangement rate: 4.2%, average chain length: 289 b).

COMPARATIVE EXAMPLE 5

A double stranded chain-shortened polynucleotide (double stranded RNA) was prepared by combining polyinosinic acid (phosphate rearrangement rate: 4.2%) with polycytidylic acid (phosphate rearrangement rate: 3.8%), which have been prepared in Examples 11 and 12, respectively. The said double stranded chain-shortened polynucleotides was prepared by dissolving sodium polyinosinate and sodium polycytidylate into Tris-HCl buffer (pH 7, containing 0.15 M NaCl), heating the solution at 80°C for 5 minutes, and gradually cooling the solution.

EXPERIMENT 1 Influence of Average Chain Length on

Pharmacological Activity

The pharmacological activity of the composition of Example 9 was evaluated *in vitro* according to the growth inhibitory action on HeLa S3 cancer cells. HeLa S3 cancer cells were inoculated in 96-well plate at a density of 10^4 cell/well and cultured for 24 hours or longer, when the sufficient adhesion of the cell to the plate was confirmed. To the plate was added a composition of the present invention, and the cultivation was continued. After 3-day-cultivation in a CO₂ incubator, the number of viable cells was counted by an MTT method. The cell growth inhibition rate was calculated according to the following formula (I). The results are shown in Table

5.

Cell growth inhibition rate (%) =

$$\frac{\text{Absorbance of complex-treated group}}{\text{Absorbance of control group}} \times 100 \quad (I)$$

Table 5

Average chain length (Phosphate rearrangement rate)		Cell growth inhibition rate against cancer cell HeLa S3 (%)				
		Concentration of poly(I),Na + poly(C),Na				
Poly(I)*	Poly(C)**	0.1	1	10	100	1000
>>1000 b ^(a)	>>1000 b ^(b)	86	100	100	100	100
1419 b (0.1%)	1923 b (0.1%)	79	98	100	100	100
982 b (0.1%)	907 b (0.2%)	65	96	100	100	100
524 b (0.4%)	489 b (0.3%)	23	85	98	100	100
360 b (0.2%)	318 b (0.1%)	17	70	97	100	100
118 b (1.2%)	139 b (0.8%)	9	45	89	98	100
84 b (1.8%)	76 b (1.2%)	0	0	6	72	92
32 b (6.8%)	27 b (4.2%)	0	0	0	18	48

*: poly(I)= polyinosinic acid

poly(I), Na= polyinosinate, sodium salt

**:: poly(C)= polycytidylic acid

poly(C),Na= polycytidylate, sodium salt

5 (a): polyinosinate, sodium salt (Yamasa Corporation)

(b): polycytidylate, sodium salt (Yamasa Corporation)

It is apparent from Table 5 that the cell growth inhibiting action of each composition on HeLa S3, a cancer cell strain, is highly correlated with the average chain length. Table 5 reveals that

10 polyinosinic-polycytidylic acids having long chain length of more than 1,000 b, which are generally used as interferon inducing agents, show the strongest growth inhibiting action. The chain-shortened polyinosinic-polycytidylic acids of the present invention having an average chain length ranging from 0.1 kb to 1 kb and containing less

15 phosphate groups rearranged still have sufficiently high growth inhibiting activity, although it is slightly lower. Such a growth inhibitory action decreased steeply in a polynucleotide having the average chain length of under 100 b, and those having the average chain length similar to that of oligonucleotides show little action.

20 EXPEIMENT 2 Influence on Marrow Cells

The toxicity evaluation was carried out on the basis of the toxicity on bone marrow. Male ddY mice (male, 8 week old) were

administered by intravenous injection each of the following samples:
commercially available sodium polyinosinate ($S^{\circ}_{20,w}$ (sedimentation
constant): 8.8, Yamasa Corporation) and sodium polycytidylylate ($S^{\circ}_{20,w}$
(sedimentation constant): 8.6, Yamasa Corporation), and polyinosinic
5 acid and polycytidylic acid containing less phosphate groups
rearranged, which have the average chain length of 982 b and 907 b,
respectively, and are prepared in Examples 5 and 6. On the next day,
bone marrow cells were collected from thigh bone, stained with New
methylene blue and Giemsa, and observed to count the numbers of
10 reticulocytes and matured erythrocytes. The results are shown in
Table 6, wherein the bone marrow toxicity is expressed as a ratio of
the number of reticulocytes to the total number of matured
erythrocytes as defined by the following formula. The mark *
means that there is a significant difference based on the multi-
15 comparison method of Dunnett at significant level of $p < 0.01$ between
the test group and control group received intravenous administration
of a vehicle without polynucleotide.

$$\text{Bone marrow toxicity} = \frac{\text{Number of reticulocyte}}{\text{Number of reticulocyte} + \text{Number of matured erythrocyte}}$$

Table 6

Average chain length		Dose	Bone marrow toxicity	Difference from Control
Poly(I) ¹⁾	Poly(C) ²⁾			
>>1000 b ^(a)	>>1000 b ^(b)	1 mg/kg	0.23*	39%
		5 mg/kg	0.15*	61%
982 b	907 b	5 mg/kg	0.31	17%
		25 mg/kg	0.29	24%

1) poly(I) = polyinosinic acid

2) poly(C) = polycytidylic acid

(a) polyinosinate, sodium salt (Yamasa Corporation)

(b) polycytidylylate, sodium salt (Yamasa Corporation)

It is apparent from Table 6 that the change in bone marrow
25 toxicity based on that of control reached as high as 39 % at the dosage

of 1 mg/kg in the cases of polyinosinic-polycytidylic acid which has a long chain length of over 1,000 b and are generally used as an interferon inducing agent, while there is no significant difference compared to control in the cases of the chain-shortened

5 polyinosinic-polycytidylic acid which has an average chain length between 0.1 kb and 1 kb and contains less phosphate groups rearranged even at 25-fold dosage. The results above revealed that the toxicity of polyinosinic acid and polycytidylic acid is highly correlated with the average chain length, similar to pharmacological
10 activity thereof. It was unexpectedly surprising finding that the chain-shortened polynucleotide of the present invention could improve such a toxicity significantly.

EXPERIMENT 3 Cell Growth Inhibitory Action (*in vitro*) on A431 Cancer Cell (average chain length: 200 ± 50 b)

15 A composition was prepared in a manner similar to that described in Example 9 using the polyinosinic acid (phosphate rearrangement rate: 0.7 - 4.2%) and polycytidylic acid (phosphate rearrangement rate: 1.2 - 3.8%) obtained in Examples 11 and 12, and the chain-shortened polyinosinic acid and polycytidylic acid obtained
20 in Examples 1 and 2. A431 cancer cells were inoculated in a 96-well plate at a density of 10^4 cell/well and cultured for 5 hours or longer, when the sufficient adhesion of the cell to the plate was confirmed. To the plate was added each of the composition and cultivation was continued. After 3-day-cultivation in a CO₂ incubator, the number of
25 viable cells was counted by an MTT method. The cell growth inhibition rate was calculated according to the formula (I), and the total concentration of sodium polyinosinate and sodium polycytidylate corresponding to 50% cell growth inhibition rate (IC₅₀) was calculated. The results are shown in Table 7.

Table 7

		Phosphate rearrangement rate of polyinosinic acid				
		0.2%	0.7%	2.0%	2.8%	4.2%
Phosphate rearrangement rate of polycytidylic acid	0.1%	1.2	1.2	1.3	3.5	6.5
	1.2%	1.1	1.2	1.4	5.6	10
	1.9%	1.2	1.3	1.4	8.2	17
	2.7%	4.2	6.2	10	17	36
	3.8%	7.8	11	23	41	66
		50% cell growth inhibition concentration (ng/ml) against A431 cancer cells				

As apparent from Table 7, the cell growth inhibiting action of the composition on A431 cancer cell was highly correlated with the phosphate rearrangement rate. That is, as the increase of phosphate groups rearranged from 3' position to 2' position, the growth inhibiting action tends to become weaker, irrespective of polyinosinic acid or polycytidylic acid. It is notable that the growth inhibiting action was remarkably strong in a combination of chain-shortened polyinosinic acid with chain-shortened polycytidylic acid each containing less phosphate groups rearranged (phosphate rearrangement rate is 3% or less, particularly 2% or less) of the present invention. On the other hand, in a combination of polyinosinic acid with polycytidylic acid each having a phosphate rearrangement rate of more than 2%, particularly 3% or more, the action tended to become weaker synergically. For example, in Table 7, a combination of polyinosinic acid (phosphate rearrangement rate: 2.0%) with polycytidylic acid (phosphate rearrangement rate: 1.9%) shows the improved IC_{50} rate by 12-fold or 47-fold as compared with combinations of polyinosinic acid (phosphate rearrangement rate: 2.8%) with polycytidylic acid (phosphate rearrangement rate: 2.7%), and polyinosinic acid (phosphate rearrangement rate: 4.2%) with polycytidylic acid (phosphate rearrangement rate: 3.8%), respectively. It was extremely unexpected that the pharmacological activity

increases thus steeply as the rearrangement rate of phosphate group from 3' position to 2' position decreases across 3%, particularly 2%, as the boundary.

EXPERIMENT 4 Influence of Phosphate Rearrangement on Melting

5 Temperature (T_m) and Pharmacological Activity

A double stranded RNA dissociates into two single stranded RNAs as the temperature is elevated to a given degree. The temperature varies depending on the kind of bases composing an RNA and is specific thereto. Accordingly, the said temperature is defined as the melting temperature of a double stranded RNA and is generally referred to as "T_m value". There are various methods for measuring the T_m value. In the present experiment, the T_m value of double stranded RNAs shown in Example 13 and Comparative Example 5 were measured by the most common method, i.e., absorptiometry.

15 The results are shown in Table 8. The IC₅₀ values shown in Table 8 are obtained in Experiment 3.

Table 8

Phosphate rearrangement rate of polyinosinic acid (%)	Phosphate rearrangement rate of polycytidylic acid (%)	Melting Temperature (T _m value) (°C)	IC ₅₀ (ng/mL)
0.2	0.1	61	1.2
0.7	1.2	62	1.2
2.0	1.9	59	1.4
2.8	2.7	59	17
4.2	3.8	58	66

As a result of measurement of the T_m value in polyinosinic - polycytidylic acid having phosphate rearrangement rate range of about 0 to 4%, no remarkable difference was found in each combination. (For polyinosinic - polycytidylic acid having long chain length generally used as interferon inducing agents, the T_m value is 61°C). It was revealed that polyinosinic - polycytidylic acid having

phosphate rearrangement rate between about 0 and 4% can form double helical structure characteristic of double stranded RNA. However, it was also revealed that the immune activating action and carcinostatic action, which are the main medicinal effects of polyinosinic - polycytidylic acid, are affected not only by the double helical structure of a double stranded RNA but also the rearrangement rate of phosphate group, because the pharmacological activity varies as much as by 4-fold to 50-fold or more when the phosphate rearrangement rate changes across 2% - 3% as the boundary, as shown in Experiment 3. In addition, it was unexpectedly surprising finding that the pharmacological activity increases steeply when the rearrangement rate of phosphate group from 3' position to 2' position changes across 2% - 3% as the boundary.

EXPERIMENT 5 Measurement of Average Chain Length of Chain-shortened Polynucleotide (GPC method)

The average chain length was measured using an aqueous solution of 1 mg/mL polynucleotide by gel permeation chromatography (GPC) under the following conditions.

GPC operating conditions:

Detection : UV at 260 nm

Column : Tosoh TSK gel G5000PWXL 7.8mm ϕ \times 300 mm

Mobile phase: 50 mM Tris-HCl buffer (pH 7.5) containing 7 M urea

Flow rate: 0.5 mL/min.

Size marker: RNA Ladder (1770 b, 1520 b, 1280 b, 780 b, 530 b, 400 b, 280 b, 155 b) (Gibco BRL)

EXPERIMENT 6 Measurement of Phosphate Rearrangement rate

- To 1 mL of an aqueous solution of 1 mg/mL polynucleotide was added 3.2 mL of aqueous solution of 500 U/mL nuclease P_1 (derived from *Penicillium citrinum*, Seikagaku Corporation), and diluted with water to make the volume 5 mL. The aqueous solution
- 5 was allowed to react for 1 hour on a water bath at 37°C. Water was added to the reaction mixture to make the volume 10 mL and 3.2 mL portion was separated therefrom. To the separated solution was added 0.8 mL of an aqueous solution of 0.1 U/mL alkaline phosphatase (derived from Calf intestine, Seikagaku Corporation),
- 10 and allowed to react on a water bath at 37°C for 30 minutes. The solution was appropriately diluted, examined by a liquid chromatography under the following conditions to determine a dimer having a 2'-5' phosphodiester bond and the phosphate rearrangement rate.
- 15 Liquid chromatography operating conditions:
- | | |
|---------------|---|
| Detection: | UV at 260 nm |
| Column: | Shiseido Capcell pack C ₁₈ UG120 5 μ m
4.6 mm ϕ \times 250 mm |
| Mobile phase: | Mixed solution (95:5) of 50 mM phosphate buffer
(pH 8) containing 5 mM tetrabutylammonium
hydrogen sulfate and methanol |
| Flow rate: | 1 mL/min. |
- 20

5/13/87

CLAIMS

1. (Amended) A chain-shortened polynucleotide or salt thereof characterized in that the proportion of a 2'-5' phosphodiester bond is in the range of 0.1% to 3% based on the whole phosphodiester bonds.

2. (Cancelled)

3. (Amended) The polynucleotide or salt thereof according to Claim 1, wherein the average chain length is between 0.1 k bases and 1 k bases.

4. (Cancelled)

5. (Amended) A method for preparing a polynucleotide or salt thereof in which the proportion of a 2'-5' phosphodiester bond is up to 3% based on the whole phosphodiester bonds and the average chain length is between 0.1 k bases and 1 k bases, characterized in that a phosphate rearrangement rate is measured in the course of the preparation.

6. (Amended) A method for preparing a chain-shortened polynucleotide or salt thereof in which the proportion of a 2'-5' phosphodiester bond is up to 3% based on the whole phosphodiester bonds, characterized in that a polynucleotide or salt thereof is reacted in a solution at pH 7 to 10 at temperature between 20 and 110°C to shorten the chain with measuring a phosphate rearrangement rate..

7. (Amended) A method for preparing a chain-shortened polynucleotide or salt thereof in which the proportion of a 2'-5' phosphodiester bond is up to 3% based on the whole phosphodiester bonds, characterized in that a polynucleotide or salt thereof is treated with a phosphodiesterase for chain-shortening with measuring a phosphate rearrangement rate..

8. (Cancelled)

FILED
MAY 31 1967

- 9. (Cancelled)
- 10. (Cancelled)
- 11. (Cancelled)
- 12. (Cancelled)
- 13. (Cancelled)

14. (Added) A polynucleotide or salt thereof in which the average chain length is between 0.1 k bases and 1 k bases, characterized in that the proportion of a 2'-5' phosphodiester bond is in the range of 0.1% to 3% based on the whole phosphodiester bonds.

15. (Added) The polynucleotide or salt thereof according to any one of Claims 1, 3, and 14, wherein the polynucleotide is polyinosinic acid or analogue thereof, polycytidylic acid or analogue thereof, polyadenylic acid or analogue thereof, polyuridylic acid or analogue thereof.

16. (Added) A polynucleotide or salt thereof according to any one of Claims 1, 3, 14, and 15, which is in form of a double stranded polynucleotide or salt thereof formed from two polynucleotides or salts thereof which are capable of forming a double strand..

17. (Added) The double stranded polynucleotide or salt thereof according to Claim 16, wherein two polynucleotides which are capable of forming a double strand are selected from the group consisting of a combination of polyinosinic acid and polycytidylic acid, of polyadenylic acid and polyuridylic acid, of polyinosinic acid analogue and polycytidylic acid, of polyinosinic acid and polycytidylic acid analogue, of polyinosinic acid analogue and polycytidylic acid analogue, of polyadenylic acid analogue and polyuridylic acid, of polyadenylic acid and polyuridylic acid analogue, and of polyadenylic acid analogue and polyuridylic acid analogue.

18.(Added) A composition comprising a complex formed from a carrier effective for introducing a medicament into a cell and a polynucleotide or salt thereof according to any one of Claims 1, 3, 14, and 15 or a double stranded polynucleotide or salt thereof according to Claim 16 or 17 as an essential ingredient.

19.(Added) The composition according to Claim 18, wherein the carrier effective for introducing a medicament into a cell is a positively charged carrier.

20.(Added) The composition according to Claim 19, wherein the positively charged carrier is a cationic liposome.

21.(Added) The composition according to Claim 18, wherein the carrier effective for introducing a medicament into a cell is a carrier formed from 2-O-(2-diethylaminoethyl)carbamoyl-1,3-O-dioleoylglycerol and a phospholipid as essential constituent components.

22.(Added) The composition according to any one of Claims 18 to 21, which is in the form of a pharmaceutical preparation.

23.(Added) The composition according to Claim 22, wherein the pharmaceutical preparation is an interferon inducing agent, immune activating agent, intracellular nuclease activating agent, cancer treating agent or preventive agent, or hepatitis treating agent or preventive agent.

07/20/2001

10:12

GREENBERG/TRAURIG # 000#99921#592692#8016400

NO.002

0004

PTO/SB/166 (5-00)

Approved for use through 10/31/02. OMB 0651-0022

Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Declaration and Power of Attorney for Patent Application

特許出願宣言書及び委任状

Japanese Language Declaration

日本語宣言書

私は、以下に記名された発明者として、ここに下記の通り宣言する：

As a below named inventor, I hereby declare that:

私の住所、居住の所先そして国籍は、私の氏名の後に記載された通りである。

My residence, post office address and citizenship are as stated next to my name.

下記の名称の発明について、特許請求範囲に記載され、且つ特許が与えられている発明主権に因して、私は、最初、最先かつ唯一の発明者である（唯一の氏名が記載されている場合）、或いは最初、最先かつ共同発明者である（複数の氏名が記載されている場合）と信じている。

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entered.

CHAIN-SHORTENED POLYNUCLEOTIDE
AND METHOD OF PREPARATION THEREOF

上記発明の明細書はここに添付されているが、下記の欄がチェックされている場合は、この限りでない：

the specification of which is attached hereto unless the following box is checked:

☐ _____ の日に提出され、
この出願の米国出願番号または外国出願番号は、
_____ であり、且つ
_____ の日に補正された出願（該当する場合）

☐ was filed on _____
as United States Application Number or
PCT International Application Number
_____ and was amended on
_____ (if applicable).

私は、上記の補正事によって補正された、特許請求範囲を含む上記明細書と改訂し、且つ内容を理解しているときここに表明する。

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

私は、連邦規則第37編規則1.56に定められている、特許性について重要な情報を開示する義務があることを認める。

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

Burden Hour Statement: This form is estimated to take 04 hours to complete. Time will vary depending upon the need of the individual case. Any comments on the amount of time you are required to complete this form should be sent to Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents and Trademarks, Washington, DC 20231.

07/20/2001

10:12

GREENBERG /TRAURIG → 000#99921#69269288016408

NO. 002

D005

PTO/SB/106 (5-00)

Approved for use through 1/23/02. OMB 0651-0032
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Japanese Language Declaration
(日本語宣言書)

私は、ここに、以下に記述した外国での特許出願または発明者証の出版、或いは外国以外の少なくとも一國を指定している米国特許第365条第3項(a)によるPCT国際出願について、同第119条(b)(4)項又は第365条(b)項に基づいて優先権を主張するとともに、優先権を主張する本出願の出発日より前の発明日を有する外国での特許出願または発明者証の出版、或いはPCT国際出願については、いかなる出願も、下記の枠内でチェックすることにより示した。

I hereby claim foreign priority under Title 35, United States Code, Section 119(b)(4) or 365(a) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT international application having a filing date before that of the application for which priority is claimed.

Prior Foreign Application(s)

外国での先行出願

Hei-11/035,963

Japan

15/2/99

Priority Not Claimed
優先権主張なし

(Number)

(Country)

(Day/Month/Year Filed)

(番号)

(国名)

(出願日/月/年)

PCT/JP00/00778

PCT

14/2/00

(Number)

(Country)

(Day/Month/Year Filed)

(番号)

(国名)

(出願日/月/年)

私は、ここに、下記のいかなる米国特許出願についても、その米国特許第365条第119条(a)項の利益を主張する。

I hereby claim the benefit under Title 35, United States Code, Section 119(a) of any United States provisional application(s) listed below.

(Application No.)

(出願番号)

(Filing Date)

(出願日)

(Application No.)

(出願番号)

(Filing Date)

(出願日)

私は、ここに、下記のいかなる米国出願についても、その米国特許第365条第119条に基づいて利益を主張し、又米国を指定するいかなるPCT国際出願についても、その同第365条(a)項に基づいて利益を主張する。また、本出願の特許請求の範囲の主題が、米国特許第365条第119条第1段に規定された発明で、先行する米国出願又はPCT国際出願に開示されている場合においては、その先行出願の出願日と本国内出願日またはPCT国際出願日との間の期間中に入手された情報で、本発明を米国特許第37編規則1.56に定められた特許性に関わる重要な情報について開示があることを主張する。

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s), or 265(c) of any PCT international application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code Section 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of application.

(Application No.)

(出願番号)

(Filing Date)

(出願日)

(Status: Patented, Pending, Abandoned)

(状況: 特許許可、待審中、放棄)

(Application No.)

(出願番号)

(Filing Date)

(出願日)

(Status: Patented, Pending, Abandoned)

(状況: 特許許可、待審中、放棄)

私は、ここに表明された私の自らの知識に資する陳述が真実であり、且つ信頼と信するに足るに基づく陳述が、真実であると信じられることを宣言し、さらに、故意に虚偽の陳述などを行った場合は、米国特許第16編第1001条に基づき、罰金または拘留、若しくはその両方により処罰され、またそのような虚偽による虚偽の陳述は、本出願またはそれに続く先行されるいかなる特許も、その有効性に損傷が生ずることを理解した上で陳述が行われたことを、ここに宣言する。

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

PTO/SB/106 (5-00)

Approved for use through 10/31/02. ONB 0031-0032
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

(Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.)

Japanese Language Declaration (日本語宣言書)

委任状: 私は本出願を審査する手続を行い、且つ米国特許審判所と
の全ての業務を遂行するために、氏名を記した発明者として、下記の発
明士及び/または弁護士を任命する。(氏名及び登録番号を記載する
こと)

POWER OF ATTORNEY: As a named inventor, I hereby appoint
the following attorney(s) and/or agent(s) to prosecute the
application and conduct all business in the Patent and Trademark Office
connected therewith (list name and registration number).

郵便送付先

Albert L. Jacobs, Jr. Reg. No. 22,211
Eugene C. Rzuwido Reg. No. 31,500
Joseph M. Manak Reg. No. 33,013
Gerard F. Diebner Reg. No. 31,345

Send Correspondence to:

Greenberg Traurig LLP
885 Third Avenue
21st floor
New York, NY 10022

直接電話送付先 (氏名及び電話番号)

Mark A. Farley Reg. No. 33,170
Alan P. Force Reg. No. 39,873
Elizabeth S. Lapadula Reg. No. 46,001
Paul J. Sutton Reg. No. 24,201
Anthony Barkume Reg. No. 33,831

Direct Telephone Calls to (name and telephone number)

Eugene C. Rzuwido, Esq.
(212) 801-2146

第一発明者氏名

Full name of sole or first inventor

発明者の署名	日付	1-00	Shinji MATSUYAMA
住所			Shinji Matsuyama July 30, 2001
国籍			Kyoto 607-8186 JAPAN JPK
郵便の宛先			7, Oyake Wasenouchicho, Yamashina-ku, Kyoto-shi, KYOTO, JAPAN 607-8186

第二共同発明者がある場合、その氏名

Full name of second joint inventor, if any

第二共同発明者の署名	日付	2-00	Kouichi ISHIYAMA
住所			Kouichi Ishiyama July 26, 2001
国籍			Ibaraki 305-0035 JAPAN JPK
郵便の宛先			Room 305, Building No. 2 25, Matsushiro 3-chome, Tsukuba-shi, Ibaraki 305-0035 JAPAN

(第三以下の共同発明者についても同様に記載し、署名を
すること)

(Supply similar information and signature for third and subsequent
joint inventors.)

07/20/2001

10:12

GREENBERG/TRAURIG → 000#99921#652692#8016400

NO.002 0007

PTOGB/106(5-00)

Approved for use through 10/31/02. OMB 0631-0002

Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Japanese Language Declaration

(日本語宣言書)

第一または第一発明者氏名

Full name of ^{third} first inventor

Junzo SEKI

発明者の署名

日付

Inventor's signature

Date

Junzo Seki

July 30, 2001

住所

Residence

Osaka 567-0032 JAPAN

国籍

Citizenship

Japan

郵便の宛先

Post Office Address

13-11, Nishiekimaecho Ibaraki-shi,

Osaka 567-0032 JAPAN

第二共同発明者がいる場合、その氏名

Full name of ^{fourth} second inventor, if any

Tadaaki OHGI

第二共同発明者の署名

日付

Second inventor's signature

Date

Tadaaki Ohgi

Jul 26, 2001

住所

Residence

Ibaraki 300-0013 JAPAN

国籍

Citizenship

Japan

郵便の宛先

Post Office Address

3628-80, Kandatsumachi, Tsuchiura-shi,

Ibaraki 300-0013 JAPAN

(第三以下の共同発明者についても同様に記載し、署名をすること)

(Supply similar information and signature for third and subsequent joint inventors.)